Approval · Notice of Compliance 31501 · 2023
HYDROMORPH CONTIN: Notice of Compliance 31501
Issued August 28, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31501
- Date
- August 28, 2023
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM). Conversion of the Product Monograph to 2020 Format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HYDROMORPH CONTIN | Not yet assigned | — |
Medicinal ingredients
- HYDROMORPHONE HCL 3 MG per CAP
- HYDROMORPHONE HCL 4.5 MG per CAP
- HYDROMORPHONE HCL 6 MG per CAP
- HYDROMORPHONE HCL 9 MG per CAP
- HYDROMORPHONE HCL 10 MG per CAP
- HYDROMORPHONE HCL 12 MG per CAP
- HYDROMORPHONE HCL 18 MG per CAP
- HYDROMORPHONE HCL 20 MG per CAP
- HYDROMORPHONE HCL 24 MG per CAP
- HYDROMORPHONE HCL 30 MG per CAP